Global Hereditary Angioedema Drug Market Growth 2025-2031

October 2025 | 93 pages | ID: G04FEB50DA8EEN
LP Information

Abstracts

The global Hereditary Angioedema Drug market size is predicted to grow from US$ 850 million in 2025 to US$ 1280 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Hereditary Angioedema Drug Industry Forecast? looks at past sales and reviews total world Hereditary Angioedema Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Hereditary Angioedema Drug sales for 2025 through 2031. With Hereditary Angioedema Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hereditary Angioedema Drug industry.

This Insight Report provides a comprehensive analysis of the global Hereditary Angioedema Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hereditary Angioedema Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Hereditary Angioedema Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hereditary Angioedema Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hereditary Angioedema Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Hereditary Angioedema Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• C1 Esterase Inhibitor
• Kallikrein Inhibitor
• Selective Bradykinin B2 Receptor Antagonist

Segmentation by Application:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Pharming Group NV
• Takeda
• CSL Limited
• IBio Inc.
• BioCryst Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hereditary Angioedema Drug market?
What factors are driving Hereditary Angioedema Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hereditary Angioedema Drug market opportunities vary by end market size?
How does Hereditary Angioedema Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Hereditary Angioedema Drug Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Hereditary Angioedema Drug by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Hereditary Angioedema Drug by Country/Region, 2020, 2024 & 2031
2.2 Hereditary Angioedema Drug Segment by Type
  2.2.1 C1 Esterase Inhibitor
  2.2.2 Kallikrein Inhibitor
  2.2.3 Selective Bradykinin B2 Receptor Antagonist
2.3 Hereditary Angioedema Drug Sales by Type
  2.3.1 Global Hereditary Angioedema Drug Sales Market Share by Type (2020-2025)
  2.3.2 Global Hereditary Angioedema Drug Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Hereditary Angioedema Drug Sale Price by Type (2020-2025)
2.4 Hereditary Angioedema Drug Segment by Application
  2.4.1 Retail Pharmacies
  2.4.2 Hospital Pharmacies
  2.4.3 Online Pharmacies
2.5 Hereditary Angioedema Drug Sales by Application
  2.5.1 Global Hereditary Angioedema Drug Sale Market Share by Application (2020-2025)
  2.5.2 Global Hereditary Angioedema Drug Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Hereditary Angioedema Drug Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Hereditary Angioedema Drug Breakdown Data by Company
  3.1.1 Global Hereditary Angioedema Drug Annual Sales by Company (2020-2025)
  3.1.2 Global Hereditary Angioedema Drug Sales Market Share by Company (2020-2025)
3.2 Global Hereditary Angioedema Drug Annual Revenue by Company (2020-2025)
  3.2.1 Global Hereditary Angioedema Drug Revenue by Company (2020-2025)
  3.2.2 Global Hereditary Angioedema Drug Revenue Market Share by Company (2020-2025)
3.3 Global Hereditary Angioedema Drug Sale Price by Company
3.4 Key Manufacturers Hereditary Angioedema Drug Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Hereditary Angioedema Drug Product Location Distribution
  3.4.2 Players Hereditary Angioedema Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR HEREDITARY ANGIOEDEMA DRUG BY GEOGRAPHIC REGION

4.1 World Historic Hereditary Angioedema Drug Market Size by Geographic Region (2020-2025)
  4.1.1 Global Hereditary Angioedema Drug Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Hereditary Angioedema Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Hereditary Angioedema Drug Market Size by Country/Region (2020-2025)
  4.2.1 Global Hereditary Angioedema Drug Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Hereditary Angioedema Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Hereditary Angioedema Drug Sales Growth
4.4 APAC Hereditary Angioedema Drug Sales Growth
4.5 Europe Hereditary Angioedema Drug Sales Growth
4.6 Middle East & Africa Hereditary Angioedema Drug Sales Growth

5 AMERICAS

5.1 Americas Hereditary Angioedema Drug Sales by Country
  5.1.1 Americas Hereditary Angioedema Drug Sales by Country (2020-2025)
  5.1.2 Americas Hereditary Angioedema Drug Revenue by Country (2020-2025)
5.2 Americas Hereditary Angioedema Drug Sales by Type (2020-2025)
5.3 Americas Hereditary Angioedema Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Hereditary Angioedema Drug Sales by Region
  6.1.1 APAC Hereditary Angioedema Drug Sales by Region (2020-2025)
  6.1.2 APAC Hereditary Angioedema Drug Revenue by Region (2020-2025)
6.2 APAC Hereditary Angioedema Drug Sales by Type (2020-2025)
6.3 APAC Hereditary Angioedema Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Hereditary Angioedema Drug by Country
  7.1.1 Europe Hereditary Angioedema Drug Sales by Country (2020-2025)
  7.1.2 Europe Hereditary Angioedema Drug Revenue by Country (2020-2025)
7.2 Europe Hereditary Angioedema Drug Sales by Type (2020-2025)
7.3 Europe Hereditary Angioedema Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Hereditary Angioedema Drug by Country
  8.1.1 Middle East & Africa Hereditary Angioedema Drug Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Hereditary Angioedema Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Hereditary Angioedema Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Hereditary Angioedema Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hereditary Angioedema Drug
10.3 Manufacturing Process Analysis of Hereditary Angioedema Drug
10.4 Industry Chain Structure of Hereditary Angioedema Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Hereditary Angioedema Drug Distributors
11.3 Hereditary Angioedema Drug Customer

12 WORLD FORECAST REVIEW FOR HEREDITARY ANGIOEDEMA DRUG BY GEOGRAPHIC REGION

12.1 Global Hereditary Angioedema Drug Market Size Forecast by Region
  12.1.1 Global Hereditary Angioedema Drug Forecast by Region (2026-2031)
  12.1.2 Global Hereditary Angioedema Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Hereditary Angioedema Drug Forecast by Type (2026-2031)
12.7 Global Hereditary Angioedema Drug Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Pharming Group NV
  13.1.1 Pharming Group NV Company Information
  13.1.2 Pharming Group NV Hereditary Angioedema Drug Product Portfolios and Specifications
  13.1.3 Pharming Group NV Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Pharming Group NV Main Business Overview
  13.1.5 Pharming Group NV Latest Developments
13.2 Takeda
  13.2.1 Takeda Company Information
  13.2.2 Takeda Hereditary Angioedema Drug Product Portfolios and Specifications
  13.2.3 Takeda Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Takeda Main Business Overview
  13.2.5 Takeda Latest Developments
13.3 CSL Limited
  13.3.1 CSL Limited Company Information
  13.3.2 CSL Limited Hereditary Angioedema Drug Product Portfolios and Specifications
  13.3.3 CSL Limited Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 CSL Limited Main Business Overview
  13.3.5 CSL Limited Latest Developments
13.4 IBio Inc.
  13.4.1 IBio Inc. Company Information
  13.4.2 IBio Inc. Hereditary Angioedema Drug Product Portfolios and Specifications
  13.4.3 IBio Inc. Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 IBio Inc. Main Business Overview
  13.4.5 IBio Inc. Latest Developments
13.5 BioCryst Pharmaceuticals, Inc.
  13.5.1 BioCryst Pharmaceuticals, Inc. Company Information
  13.5.2 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolios and Specifications
  13.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 BioCryst Pharmaceuticals, Inc. Main Business Overview
  13.5.5 BioCryst Pharmaceuticals, Inc. Latest Developments
13.6 Ionis Pharmaceuticals, Inc.
  13.6.1 Ionis Pharmaceuticals, Inc. Company Information
  13.6.2 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolios and Specifications
  13.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Ionis Pharmaceuticals, Inc. Main Business Overview
  13.6.5 Ionis Pharmaceuticals, Inc. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Hereditary Angioedema Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Hereditary Angioedema Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of C1 Esterase Inhibitor
Table 4. Major Players of Kallikrein Inhibitor
Table 5. Major Players of Selective Bradykinin B2 Receptor Antagonist
Table 6. Global Hereditary Angioedema Drug Sales by Type (2020-2025) & (K Units)
Table 7. Global Hereditary Angioedema Drug Sales Market Share by Type (2020-2025)
Table 8. Global Hereditary Angioedema Drug Revenue by Type (2020-2025) & ($ million)
Table 9. Global Hereditary Angioedema Drug Revenue Market Share by Type (2020-2025)
Table 10. Global Hereditary Angioedema Drug Sale Price by Type (2020-2025) & (USD/Unit)
Table 11. Global Hereditary Angioedema Drug Sale by Application (2020-2025) & (K Units)
Table 12. Global Hereditary Angioedema Drug Sale Market Share by Application (2020-2025)
Table 13. Global Hereditary Angioedema Drug Revenue by Application (2020-2025) & ($ million)
Table 14. Global Hereditary Angioedema Drug Revenue Market Share by Application (2020-2025)
Table 15. Global Hereditary Angioedema Drug Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Hereditary Angioedema Drug Sales by Company (2020-2025) & (K Units)
Table 17. Global Hereditary Angioedema Drug Sales Market Share by Company (2020-2025)
Table 18. Global Hereditary Angioedema Drug Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Hereditary Angioedema Drug Revenue Market Share by Company (2020-2025)
Table 20. Global Hereditary Angioedema Drug Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Hereditary Angioedema Drug Producing Area Distribution and Sales Area
Table 22. Players Hereditary Angioedema Drug Products Offered
Table 23. Hereditary Angioedema Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Hereditary Angioedema Drug Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Hereditary Angioedema Drug Sales Market Share Geographic Region (2020-2025)
Table 28. Global Hereditary Angioedema Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Hereditary Angioedema Drug Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Hereditary Angioedema Drug Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Hereditary Angioedema Drug Sales Market Share by Country/Region (2020-2025)
Table 32. Global Hereditary Angioedema Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Hereditary Angioedema Drug Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Hereditary Angioedema Drug Sales by Country (2020-2025) & (K Units)
Table 35. Americas Hereditary Angioedema Drug Sales Market Share by Country (2020-2025)
Table 36. Americas Hereditary Angioedema Drug Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Hereditary Angioedema Drug Sales by Type (2020-2025) & (K Units)
Table 38. Americas Hereditary Angioedema Drug Sales by Application (2020-2025) & (K Units)
Table 39. APAC Hereditary Angioedema Drug Sales by Region (2020-2025) & (K Units)
Table 40. APAC Hereditary Angioedema Drug Sales Market Share by Region (2020-2025)
Table 41. APAC Hereditary Angioedema Drug Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Hereditary Angioedema Drug Sales by Type (2020-2025) & (K Units)
Table 43. APAC Hereditary Angioedema Drug Sales by Application (2020-2025) & (K Units)
Table 44. Europe Hereditary Angioedema Drug Sales by Country (2020-2025) & (K Units)
Table 45. Europe Hereditary Angioedema Drug Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Hereditary Angioedema Drug Sales by Type (2020-2025) & (K Units)
Table 47. Europe Hereditary Angioedema Drug Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Hereditary Angioedema Drug Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Hereditary Angioedema Drug Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Hereditary Angioedema Drug Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa Hereditary Angioedema Drug Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Hereditary Angioedema Drug
Table 53. Key Market Challenges & Risks of Hereditary Angioedema Drug
Table 54. Key Industry Trends of Hereditary Angioedema Drug
Table 55. Hereditary Angioedema Drug Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Hereditary Angioedema Drug Distributors List
Table 58. Hereditary Angioedema Drug Customer List
Table 59. Global Hereditary Angioedema Drug Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global Hereditary Angioedema Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Hereditary Angioedema Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas Hereditary Angioedema Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Hereditary Angioedema Drug Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC Hereditary Angioedema Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Hereditary Angioedema Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe Hereditary Angioedema Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Hereditary Angioedema Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Hereditary Angioedema Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Hereditary Angioedema Drug Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global Hereditary Angioedema Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Hereditary Angioedema Drug Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global Hereditary Angioedema Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Pharming Group NV Basic Information, Hereditary Angioedema Drug Manufacturing Base, Sales Area and Its Competitors
Table 74. Pharming Group NV Hereditary Angioedema Drug Product Portfolios and Specifications
Table 75. Pharming Group NV Hereditary Angioedema Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Pharming Group NV Main Business
Table 77. Pharming Group NV Latest Developments
Table 78. Takeda Basic Information, Hereditary Angioedema Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Takeda Hereditary Angioedema Drug Product Portfolios and Specifications
Table 80. Takeda Hereditary Angioedema Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Takeda Main Business
Table 82. Takeda Latest Developments
Table 83. CSL Limited Basic Information, Hereditary Angioedema Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. CSL Limited Hereditary Angioedema Drug Product Portfolios and Specifications
Table 85. CSL Limited Hereditary Angioedema Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. CSL Limited Main Business
Table 87. CSL Limited Latest Developments
Table 88. IBio Inc. Basic Information, Hereditary Angioedema Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. IBio Inc. Hereditary Angioedema Drug Product Portfolios and Specifications
Table 90. IBio Inc. Hereditary Angioedema Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. IBio Inc. Main Business
Table 92. IBio Inc. Latest Developments
Table 93. BioCryst Pharmaceuticals, Inc. Basic Information, Hereditary Angioedema Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolios and Specifications
Table 95. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. BioCryst Pharmaceuticals, Inc. Main Business
Table 97. BioCryst Pharmaceuticals, Inc. Latest Developments
Table 98. Ionis Pharmaceuticals, Inc. Basic Information, Hereditary Angioedema Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolios and Specifications
Table 100. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Ionis Pharmaceuticals, Inc. Main Business
Table 102. Ionis Pharmaceuticals, Inc. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Hereditary Angioedema Drug
Figure 2. Hereditary Angioedema Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Hereditary Angioedema Drug Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Hereditary Angioedema Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Hereditary Angioedema Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Hereditary Angioedema Drug Sales Market Share by Country/Region (2024)
Figure 10. Hereditary Angioedema Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of C1 Esterase Inhibitor
Figure 12. Product Picture of Kallikrein Inhibitor
Figure 13. Product Picture of Selective Bradykinin B2 Receptor Antagonist
Figure 14. Global Hereditary Angioedema Drug Sales Market Share by Type in 2025
Figure 15. Global Hereditary Angioedema Drug Revenue Market Share by Type (2020-2025)
Figure 16. Hereditary Angioedema Drug Consumed in Retail Pharmacies
Figure 17. Global Hereditary Angioedema Drug Market: Retail Pharmacies (2020-2025) & (K Units)
Figure 18. Hereditary Angioedema Drug Consumed in Hospital Pharmacies
Figure 19. Global Hereditary Angioedema Drug Market: Hospital Pharmacies (2020-2025) & (K Units)
Figure 20. Hereditary Angioedema Drug Consumed in Online Pharmacies
Figure 21. Global Hereditary Angioedema Drug Market: Online Pharmacies (2020-2025) & (K Units)
Figure 22. Global Hereditary Angioedema Drug Sale Market Share by Application (2024)
Figure 23. Global Hereditary Angioedema Drug Revenue Market Share by Application in 2025
Figure 24. Hereditary Angioedema Drug Sales by Company in 2025 (K Units)
Figure 25. Global Hereditary Angioedema Drug Sales Market Share by Company in 2025
Figure 26. Hereditary Angioedema Drug Revenue by Company in 2025 ($ millions)
Figure 27. Global Hereditary Angioedema Drug Revenue Market Share by Company in 2025
Figure 28. Global Hereditary Angioedema Drug Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Hereditary Angioedema Drug Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Hereditary Angioedema Drug Sales 2020-2025 (K Units)
Figure 31. Americas Hereditary Angioedema Drug Revenue 2020-2025 ($ millions)
Figure 32. APAC Hereditary Angioedema Drug Sales 2020-2025 (K Units)
Figure 33. APAC Hereditary Angioedema Drug Revenue 2020-2025 ($ millions)
Figure 34. Europe Hereditary Angioedema Drug Sales 2020-2025 (K Units)
Figure 35. Europe Hereditary Angioedema Drug Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Hereditary Angioedema Drug Sales 2020-2025 (K Units)
Figure 37. Middle East & Africa Hereditary Angioedema Drug Revenue 2020-2025 ($ millions)
Figure 38. Americas Hereditary Angioedema Drug Sales Market Share by Country in 2025
Figure 39. Americas Hereditary Angioedema Drug Revenue Market Share by Country (2020-2025)
Figure 40. Americas Hereditary Angioedema Drug Sales Market Share by Type (2020-2025)
Figure 41. Americas Hereditary Angioedema Drug Sales Market Share by Application (2020-2025)
Figure 42. United States Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Hereditary Angioedema Drug Sales Market Share by Region in 2025
Figure 47. APAC Hereditary Angioedema Drug Revenue Market Share by Region (2020-2025)
Figure 48. APAC Hereditary Angioedema Drug Sales Market Share by Type (2020-2025)
Figure 49. APAC Hereditary Angioedema Drug Sales Market Share by Application (2020-2025)
Figure 50. China Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. India Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Hereditary Angioedema Drug Sales Market Share by Country in 2025
Figure 58. Europe Hereditary Angioedema Drug Revenue Market Share by Country (2020-2025)
Figure 59. Europe Hereditary Angioedema Drug Sales Market Share by Type (2020-2025)
Figure 60. Europe Hereditary Angioedema Drug Sales Market Share by Application (2020-2025)
Figure 61. Germany Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 62. France Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Hereditary Angioedema Drug Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Hereditary Angioedema Drug Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Hereditary Angioedema Drug Sales Market Share by Application (2020-2025)
Figure 69. Egypt Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Hereditary Angioedema Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Hereditary Angioedema Drug in 2025
Figure 75. Manufacturing Process Analysis of Hereditary Angioedema Drug
Figure 76. Industry Chain Structure of Hereditary Angioedema Drug
Figure 77. Channels of Distribution
Figure 78. Global Hereditary Angioedema Drug Sales Market Forecast by Region (2026-2031)
Figure 79. Global Hereditary Angioedema Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Hereditary Angioedema Drug Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Hereditary Angioedema Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Hereditary Angioedema Drug Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Hereditary Angioedema Drug Revenue Market Share Forecast by Application (2026-2031)